ANDA 203966, held by Torrent Pharmaceuticals. Nebivolol Hydrochloride.
As of Nov 21, 2026, ANDA 203966 (Nebivolol Hydrochloride), held by Torrent Pharmaceuticals, was first approved by FDA on Mar 2, 2018, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 2, 2018 | Original application | Approved | None posted |
| Nebivolol HydrochlorideEQ 2.5MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 5MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 10MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 20MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Oct 30, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 2, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters